Pharmaceuticals

Preventive Vaccines Market 2026–2035 strengthening with immunization programs

March 24, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Preventive Vaccines Market Over The Period 2026–2030?

The preventive vaccines market has experienced substantial expansion in recent years. Projections indicate it will grow from $83 billion in 2025 to $90.33 billion in 2026, at a compound annual growth rate (CAGR) of 8.8%. Historically, this growth has been fueled by factors such as the successful eradication and control of infectious diseases, various government-led vaccination efforts, a rise in public health consciousness, the establishment of worldwide immunization programs, and enhanced funding from global health organizations.

The preventive vaccines market is projected to experience robust expansion over the coming years. It is anticipated to grow to $131.27 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.8%. This growth during the forecast period is primarily driven by the advancement of next-generation vaccine platforms, an increasing global population and urbanization, intensified outbreak preparedness initiatives, the expansion of adult immunization programs, and the rising number of public–private partnerships in vaccine development. Noteworthy trends in the forecast period include the broadening of national immunization programs, a greater emphasis on preventive healthcare and disease control, an increasing demand for pediatric and geriatric vaccination, the proliferation of combination and multivalent vaccines, and the strengthening of cold chain and vaccine storage infrastructure.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

Which Economic Or Industry Drivers Are Impacting The Preventive Vaccines Market?

The growing incidence of infectious diseases is anticipated to boost the expansion of the preventive vaccines market in the future. Infectious diseases are conditions resulting from pathogenic microorganisms like bacteria, viruses, fungi, or parasites, which can spread between individuals or via environmental contact. This increase in infectious disease prevalence stems from factors such as heightened urbanization, international travel, and antimicrobial resistance, all of which contribute to more rapid transmission and greater difficulty in managing infections. Preventive vaccines aid in managing infectious diseases by activating the immune system to identify and combat pathogens prior to infection, consequently lowering disease rates and spread. As an example, in 2024, the World Health Organization, an intergovernmental body located in Switzerland, disclosed that global new TB (tuberculosis) diagnoses amounted to 8.2 million in 2023, up from 7.5 million in 2022. Consequently, the rising prevalence of infectious diseases is fueling the expansion of the preventive vaccines market.

How Is The Preventive Vaccines Market Divided Into Its Major Segments?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

How Are Trends Transforming The Preventive Vaccines Market Landscape?

Leading companies in the preventive vaccines market are focusing on innovations in vaccine technology, such as sophisticated mRNA platforms, to enhance vaccine efficacy, improve safety profiles, enable faster development and manufacturing, and provide broader protection against emerging variants of infectious diseases. Advanced mRNA technology platforms involve cutting-edge methods that use messenger RNA to instruct cells to produce specific proteins, initiating a targeted immune response. For instance, in March 2025, Moderna Inc., a US-based biotechnology company, announced FDA approval for mRNA-1283 (mNEXSPIKE), a new COVID-19 vaccine. It is authorized for adults aged 65 and older and individuals aged 12–64 with one or more CDC-defined risk factors. The launch of mNEXSPIKE marks a significant advancement in next-generation mRNA vaccine technology, offering improved stability and ease of storage compared to earlier versions. This development is expected to enhance vaccine accessibility and distribution, particularly in underserved and remote areas.

Who Are The Prominent Organizations Shaping The Preventive Vaccines Market?

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Read the full preventive vaccines market report here:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

What Are The Top-Performing Regions Within The Preventive Vaccines Market?

North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Preventive Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24667&type=smp

Browse Through More Reports Similar to the Global Preventive Vaccines Market 2026, By The Business Research Company

Adult Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Travel Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/travel-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795